N, vol. 25, no. 10, pp. 66167, 2005. B. Do an, Y. Harmanyeri, H. Balo lu, and I. Oztek, “Intraleg g sional alfa-2a interferon therapy for basal cell carcinoma,” Cancer Letters, vol. 91, no. two, pp. 21519, 1995. J. J. Grob, A. M. Collett, M. H. Munoz, and J. J. Bonerandi, “Treatment of big basal-cell carcinomas with intralesional interferon-alpha 2a,” Lancet, vol. 1, no. 8590, pp. 87879, 1988. L. Edwards, B. Berman, R. P. Rapini et al., “Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy,” Archives of Dermatology, vol. 128, no. 11, pp. 1486489, 1992. P. A. DiLorenzo, N. Goodman, F. Lansville, and W. Markel, “Regional and intralesional therapy of invasive basal cell carcinoma with interferon alfa-n2b,” Journal in the American Academy of Dermatology, vol. 31, no. 1, pp. 10911, 1994. P. LeGrice, E. Baird, and L. Hodge, “Treatment of basal cell carcinoma with intralesional interferon alpha-2a,” New Zealand Healthcare Journal, vol. 108, no. 1000, pp. 20607, 1995. E. Alpsoy, E. Yilmaz, E. Basaran, and S. Yazar, “Comparison on the effects of intralesional interferon alfa-2a, 2b as well as the combination of 2a and 2b in the treatment of basal cell carcinoma,” Journal of Dermatology, vol. 23, no. 6, pp. 39496, 1996. R. R. McDonald and K. Georgouras, “Treatment of basal cell carcinoma with intralesional interferon alpha: a case report and literature critique,” Australasian Journal of Dermatology, vol. 33, no. two, pp. 816, 1992. M. Yaar, R. L. Karassik, L.Oleic acid E.Lipopolysaccharides Schnipper, and B. A. Gilchrest, “Effects of alpha and beta interferons on cultured human keratinocytes,” Journal of Investigative Dermatology, vol. 85, no. 1, pp. 704, 1985. B. J. Nickoloff, T. Y. Basham, T. C. Merigan, and V. B. Morhenn, “Antiproliferative effects of recombinant – and -interferons on cultured human keratinocytes,” Laboratory Investigation, vol. 51, no. six, pp. 69701, 1984. D. R. Bielenberg, M. F. McCarty, C. D. Bucana et al., “Expression of interferon- is connected with development arrest of murine and human epidermal cells,” Journal of Investigative Dermatology, vol. 112, no. five, pp. 80209, 1999. K. Krasagakis, C. Garbe, S. Kruger, and C. E. Orfanos, “Effects of interferons on cultured human melanocytes in vitro: interferonbeta but not-alpha or -gamma inhibit proliferation and all interferons substantially modulate the cell phenotype,” Journal of Investigative Dermatology, vol.PMID:23715856 97, no. 2, pp. 36472, 1991. A. J. Stout, I. Gresser, and W. D. Thompson, “Inhibition of wound healing in mice by local interferon / injection,” International Journal of Experimental Pathology, vol. 74, no. 1, pp. 7985, 1993. M. F. McCarty, D. Bielenberg, C. Donawho, C. D. Bucana, and I. J. Fidler, “Evidence for the causal part of endogenous interferon/ in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms,” Clinical and Experimental Metastasis, vol. 19, no. 7, pp. 60915, 2002. D. Niederwieser, J. Aubock, J. Troppmair et al., “IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in vitro alloimmune responses,” Journal of Immunology, vol. 140, no. eight, pp. 2556564, 1988. B. J. Nickoloff, T. Y. Basham, T. C. Merigan, and V. B. Morhenn, “Immunomodulatory and antiproliferative impact of recombinant alpha, beta, and gamma interferons on cultured human[10][11][12][13][14]Conflict of InterestsThe authors have no conflict of interests to report. There was no funding provided for the production of this paper.[15][.
